Tumor Control Durable With Pembrolizumab in Merkel Cell Cancer
For patients with advanced Merkel cell carcinoma (aMCC), pembrolizumab is associated with durable tumor control and favorable overall survival.
For patients with advanced Merkel cell carcinoma (aMCC), pembrolizumab is associated with durable tumor control and favorable overall survival.
The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Merkel cell carcinoma is a rare form of skin cancer associated with higher mortality rates than other skin cancers.
Investigators report a rare case of combined Merkel cell and squamous cell carcinoma confined almost exclusively to the epidermis.
Approval of avelumab for the treatment of patients 12 years and older with Merkel cell carcinoma was granted by the FDA.